Please login to the form below

Not currently logged in
Email:
Password:

Report reveals best-in-class, cross-functional marketing teams

A new Best Practices report reveals how an effective cross-functional team can lay the groundwork for a new pharmaceutical product's success in the marketplace, both initially and long-term.

A new Best Practices report reveals how an effective cross-functional team can lay the groundwork for a new pharmaceutical product's success in the marketplace, both initially and long-term.

Pharma companies say that the various activities of a cross-functional team are responsible for half of a drug's success, with the other half embedded in the biological attributes of the compound, according to Best Practices, a US-based research and consultancy company.

The report, entitled "Managing Cross-Functional Teams for Pharmaceutical Product Commercialisation Excellence", reveals the best-in-class practices implemented by leading companies use to establish effective cross-functional teams, such as empowering teams to make key decisions and make teams follow standardised processes.

In the study, companies found benefit in moving various marketing activities up in the development schedule to help understand market needs earlier in the process. A sample of study participants found that teams averaged 0.5 marketing FTEs at pre-clinical, 1.8 marketing FTEs at phase II and 5.6 marketing FTEs at launch.

Study participants included Amgen, Novartis, GlaxoSmithKline, Merck and Johnson & Johnson. Findings were based on a two-pronged research approach:
benchmark surveys were performed on more than 49 companies and interviews with directors and managers involved with managing teams across units, functions or countries.


28th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics